Bolland MJ, Grey A, Reid IR (2012) Misclassification does not explain increased cardiovascular risks of calcium supplements. J Bone Miner Res 27:959, Author reply, 960–951PubMedCrossRef 151. Grey A, Bolland M, Reid R (2011) Calcium supplements and see more cardiovascular disease—picking the spin. Int J Clin Pract 65:226–227, Author reply, 227–228PubMedCrossRef 152. Bolland MJ, Grey A, Reid IR (2011) Re: the calcium scare: what would Austin Bradford Hill have thought? Osteoporos Int 22:3079–3080, Author reply, 3081–3073PubMedCrossRef 153. Lewis JR, Zhu K, Prince RL (2012) Response to: misclassification does not explain increased cardiovascular risks of calcium supplements. J Bone Miner Res 27:960–961CrossRef

154. Lewis JR, Zhu K, Prince RL (2012)

Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting CUDC-907 concentration in randomized controlled trials of calcium supplementation. J Bone Miner Res 27:719–722PubMedCrossRef 155. Nordin BE, Lewis JR, Daly RM, Horowitz J, Metcalfe A, Lange K, Prince RL (2011) The calcium scare—what would Austin Bradford Hill have thought? Osteoporos Int 22:3073–3077PubMedCrossRef 156. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL (2011) Calcium supplementation and the risks of atherosclerotic vascular PRN1371 disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 26:35–41PubMedCrossRef 157. Rizzoli R, Burlet N, Cahall D et al (2008) Osteonecrosis of the jaw and bisphosphonate treatment for Pregnenolone osteoporosis. Bone 42:841–847PubMedCrossRef 158. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026PubMedCrossRef 159. Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239–254PubMedCrossRef 160. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532PubMedCrossRef

161. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282:637–645PubMedCrossRef 162. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama 281:2189–2197PubMedCrossRef 163. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama 295:2727–2741PubMedCrossRef 164.